Products

PE-Labeled Human HLA-A*02:01&B2M&NPM1-CLAV Tetramer

Overview Specification

Product Name	PE-Labeled Human HLA-A*02:01&B2M&NPM1-CLAV Tetramer
Cat. No.	MHCRP-0643
Category	Proteins & Peptides
Product Description	Recombinant PE-Labeled Human HLA-A02:01&B2M&NPM1-CLAV (CLAVEEVSL) Tetramer Protein is expressed from E. coli* with His tag and Avi tag at the C-terminus. PE-Labeled Human HLA-A02:01&B2M&NPM1-CLAV (CLAVEEVSL) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin. It contains Gly25-Thr305 (HLA-A02:01), Ile21-Met119 (B2M) and CLAVEEVSL peptide.
Size	100/500 μg
Format	Liquid. Supplied as 0.22 μm filtered solution in 20 mM Tris, 200 mM NaCl, 0.2% BSA (pH 8.0).
Storage	Store at -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping Temp	Shipped at ambient temperature.
Lead Time	Product delivery time depends on the supplier.
Species	Human
Expression Host	E. coli
Accession No	A0A140T913(HLA-A*02:01)&P61769(B2M)&CLAVEEVSL
Tag	C-His-Avi
Tag Position	C-terminus
Molecular Type	Tetramer
Gene Synonyms	NPM1-CLAV (CLAVEEVSL); NPM1-CLAV; CLAVEEVSL
Amino Acid Range	Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M), and CLAVEEVSL peptide
Fluorophore	PE
Product Background	The nucleophosmin (NPM1) mutant protein, a-leukemia-associated antigen-characterized by its leukemia-restricted expression and immunogenic potential, has emerged as a promising therapeutic target for acute myeloid leukemia (AML) immunotherapy. Among its immunogenic epitopes, the-CLAVEEVSL peptide-derived from the full C-terminal region of the NPM1-mutated isoform demonstrates potent immunogenicity, making it a prime candidate for T cell-based immunotherapies.
Allele	HLA-A*02:01
Biotinylated	No

For research or industrial raw materials, not for personal medical use!